Journals / Mikrobiyoloji Bülteni / 2004 / Cilt: 38 - Sayı: 4

Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients

Yoğun bakım ünitelerinde yatan hastalardan izole edilen Pseudomonas aeruginosa suşlarına karşı ertapenemin in-vitro etkinliğinin araştırılması

Pages
355–362
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In case of confirmation of our results by larger scale studies, the empiric treatment of ICU infections caused by Paeruginosa with ertapenem, should be carefully evaluated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pseudomonas aeruginosa is one of the important cause of infections in intensive care unit (ICU) patients.
📊
Key Findings & Data:Susceptibility tests were performed by using Kirby-Bauer disk diffusion method and MicroScan MERCH MIC 8 panel (MicroScan 96, Dade Behring, USA).
💡
Conclusion & Impact:In case of confirmation of our results by larger scale studies, the empiric treatment of ICU infections caused by Paeruginosa with ertapenem, should be carefully evaluated.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Yoğun bakım üniteleri · Pseudomonas aeruginosa · Karbapenemler

Abstract

Pseudomonas aeruginosa is one of the important cause of infections in intensive care unit (ICU) patients. The aim of this study was to investigate the effectiveness of ertapenem prior to its use in Turkey, against multiple-resistant Paeruginosa strains isolated from ICUs. Susceptibility tests were performed by using Kirby-Bauer disk diffusion method and MicroScan MERCH MIC 8 panel (MicroScan 96, Dade Behring, USA). While the resistance rates of ertapenem, imipenem and meropenem were 59.2%, 50% and 48.1% by disk diffusion method, they were 57.4%, 46.2% and 42.5% by MicroScan, respectively. Ertapenem was found less effective against multiple-resistant Paeruginosa isolates by both of the methods when compared with imipenem and meropenem. Piperacillin/tazobactam was detected as the most effective agent against these isolates by both of the methods. As a result, although carbapenemes are frequently used for infections caused by Paeruginosa, ertapenem, which is a new carbapenem, is not effective as much as the others. In case of confirmation of our results by larger scale studies, the empiric treatment of ICU infections caused by Paeruginosa with ertapenem, should be carefully evaluated.

Özet

Pseudomonas aeruginosa yoğun bakım üniteleri (YBÜ)'nde ciddi enfeksiyonlara neden olmaktadır. Çalışmamızın amacı, Türkiye'de henüz kullanıma girmemiş olan ertapenemin, hastanemiz YBÜ'nde yatan hastaların çeşitli klinik örneklerinden izole edilen çoğul ilaç dirençli Paeruginosa suşlarına karşı etkinliğinin iki farklı yöntemle araştırılmasıdır. Bu amaçla, Paeruginosa izolatlarının antibiyotik duyarlılıkları, Kirby-Bauer disk difüzyon yöntemi ve minimal inhibisyon konsantrasyon (MİK) tespitine dayalı MicroScan (MicroScan 96, Dade Behring, USA) yöntemiyle araştırılmıştır. Ertapenem, imipenem ve meropeneme sırasıyla disk difüzyon yöntemi ile %59.2, %50 ve %48.1, MicroScan plaklar kullanıldığında ise %57.4, %46.2 ve %42.5 oranlarında direnç saptanmıştır. Hem disk difüzyon hem de MİK sonuçlarına göre, ertapenemin çoğul ilaç dirençli Paeruginosa izolatlarına karşı imipenem ve meropenemden daha az etkili olduğu gözlenmiştir. Çalışmamızda en etkili antibiyotik, her iki yöntemle de piperasilin/tazobaktam olarak saptanmıştır. Sonuç olarak, karbapenemler Paeruginosa enfeksiyonlarının tedavisinde sıklıkla kullanılmalarına rağmen yeni bir karbapenem olan ertapenemin özellikle YBÜ'nde ortaya çıkan Paeruginosa nedenli enfeksiyonlara karşı diğer karbapenemler kadar etkili olmadığı görülmüştür. Daha fazla izolat üzerinde yapılacak çalışmalar sonuçlarımızı desteklediği taktirde, özellikle Paeruginosa'nm neden olabileceği YBÜ enfeksiyonlarının ampirik tedavisinde bu durumun dikkate alınmasının yararlı olacağını düşünmekteyiz.

🔖

Cite This Article

KILIÇ, A., KÜÇÜKKARAASLAN, A., ŞENSES, Z., BAYSALLAR, M., DOĞANCI, L. (2004). Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients. Mikrobiyoloji Bülteni, Cilt: 38 - Sayı: 4, 355–362. https://ajindex.com/articles/299654

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Pollack M. Pseudomonas aeruginosa, p. 2310-2335. İn: Mandell GL, Bennett JE, Dolin R (eds), Principles and Practice of Infectious Diseases. 2000, 5th ed. Churchill Livingstone, Philadelphia
  2. Karlowsky JA. Draghi DC, Jones ME, Thornsberry C, Friedland İR, Sahm DF: Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003, 47: 1681-1688
  3. Laethem T, De Lepeleire I, McCrea J, et al: Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimiciob Agents Chemother 2003, 47. 1439-M42
  4. Livermore DM, Sefton AM, Scott GM: Properties and potential of ertapenem. J Antimicrob Chemother 2003, 52: 331-344
  5. Musson DG, Majumdar A, Birk K, et al: Pharmacokinetics of intramuscularly administered ertapenem. Antimicrob Agents Chemother 2003, 47: 1732-1735
  6. Shah PM, Isaacs RD Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003, 52: 538-542
  7. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC (eds): Guidelines for the Collection, Transport, Processing, Analysis, and Reporting of Cultures From Spesific Specimen Sources, p. 121-162. Color Atlas and Textbook of Diagnostic Microbiology 1997, 5th ed. JB Lippincott Co, Philadelphia
  8. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility test. 2000, 7th ed. Approved Standard M2-A7, NCCLS, Villanova. PA
  9. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing 8th informational supplement. 2000, NCCLS document M100-S8. NCCLS, Villanova, PA. 10. http://www.cms.hhs.gov/clia/apcsubk2.pdf 11 Blondeau JM, Suter ME, Borsos S, Misfeldt C: Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: Focus on ciprofloxacin. Int J Antimicrob Agents 1998, 10: 297-302 12. Goossens H: Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: Results from the European MYSTIC study group. Clin Microbiol Infect 2003. 9: 980-983 13. Erdem I, Kucukercan M. Ceran N: In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Chemotherapy 2003, 49: 294-297
  10. Rhomberg